Literature DB >> 7252264

Duration of infection-derived immunity to cholera.

M M Levine, R E Black, M L Clements, L Cisneros, D R Nalin, C R Young.   

Abstract

Four volunteers were rechallenged with Vibrio cholerae (10(6) classical Ogawa 395 organisms) 33-36 months after their initial induced cholera infection; none of the four veterans and four of five control volunteers developed diarrhea (P = 0.04). All control subjects, but only one veteran, had positive coprocultures. Three of the four veterans had significant levels of serum IgG antitoxin before challenge, but none had measurable intestinal levels of secretory IgA antitoxin. Significant rises in levels of serum vibriocidal and antitoxic antibody occurred in all control subjects and in two veterans, who also manifested rises in levels of intestinal secretory IgA antitoxin. The impressive duration of infection-derived immunity suggests that the most promising approach to development of cholera vaccines may be to mimic natural immunity with orally administered, attenuated strains of V. cholerae.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7252264     DOI: 10.1093/infdis/143.6.818

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  112 in total

1.  Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Mohammad Arif Rahman; M Mohasin; Sweta M Patel; Amena Aktar; Farhana Khanam; Taher Uddin; M Asrafuzzaman Riyadh; Amit Saha; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Richelle Charles; Regina LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

2.  Vibrio cholerae-induced inflammation in the neonatal mouse cholera model.

Authors:  Anne L Bishop; Bharathi Patimalla; Andrew Camilli
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains.

Authors:  T I Crean; M John; S B Calderwood; E T Ryan
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Induction of interleukin-8 in T84 cells by Vibrio cholerae.

Authors:  Xin Zhou; Da Q Gao; Jane Michalski; Jorge A Benitez; James B Kaper
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Purification and characterization of the soluble hemagglutinin (cholera lectin)( produced by Vibrio cholerae.

Authors:  R A Finkelstein; L F Hanne
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

6.  Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

Authors:  David R Tribble; Shahida Baqar; Daniel A Scott; Michael L Oplinger; Fernando Trespalacios; David Rollins; Richard I Walker; John D Clements; Steven Walz; Paul Gibbs; Edward F Burg; Anthony P Moran; Lisa Applebee; A Louis Bourgeois
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

Review 7.  Oral vaccination against enteric bacterial infections: an overview.

Authors:  R Germanier
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

8.  Assay dependent specificities of monoclonal antibodies to bacterial antigens.

Authors:  S Ghosh; A M Campbell
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

9.  Genomic correlates of variability in immune response to an oral cholera vaccine.

Authors:  Partha P Majumder; Neeta Sarkar-Roy; Herman Staats; T Ramamurthy; Sujit Maiti; Goutam Chowdhury; Carol C Whisnant; K Narayanasamy; Diane K Wagener
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

10.  CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain.

Authors:  J Michalski; J E Galen; A Fasano; J B Kaper
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.